Template:Changes in hormone levels with bicalutamide monotherapy
Jump to navigation
Jump to search
Template documentation
- Changes in hormone levels with bicalutamide monotherapy
Testosterone levels with 10, 30, and 50 mg/day bicalutamide monotherapy in men with prostate cancer.[1]
Testosterone levels with 10 to 200 mg/day bicalutamide monotherapy in men with prostate cancer.[2]
Estradiol levels with 10, 30, and 50 mg/day bicalutamide monotherapy in men with prostate cancer.[1]
Estradiol levels with 10 to 200 mg/day bicalutamide monotherapy in men with prostate cancer.[2]
See also
References
- ↑ 1.0 1.1 Kennealey GT, Furr BJ (February 1991). "Use of the nonsteroidal anti-androgen Casodex in advanced prostatic carcinoma". Urol. Clin. North Am. 18 (1): 99–110. PMID 1992575.
- ↑ 2.0 2.1 Tyrrell CJ, Denis L, Newling D, Soloway M, Channer K, Cockshott ID (1998). "Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group". Eur. Urol. 33 (1): 39–53. doi:10.1159/000019526. PMID 9471040.
| Editors can experiment in this template's sandbox (create | mirror) and testcases (create) pages. Subpages of this template. |